The trajectory of Viagra, initially marketed by copyright, presents a intricate case study for investors considering the drug sector. Although its groundbreaking success and generation of billions in earnings , the intellectual property lapse has opened the floodgates for generic medications, greatly eroding profit opportunities. This change raises